Background: Present real-world study evaluated the effectiveness of dapagliflozin as an add-on modality, in adult patients with T2DM.

Method: We conducted an EMR-based retrospective, multicentre study in adult T2DM patients inadequately controlled on existing antidiabetic therapy and receiving dapagliflozin as add-on therapy. Baseline characteristics (visit 1) and treatment-related outcomes (visit 2 considered between 60 days-140 days after adding dapagliflozin) which included HbA1C, BMI, SBP & DBP were analyzed.

Results: 3616 patients were included from 478 centres, of which 55.7% were males. Mean age was 51 years (range: 40-64 years). Most patients had received dapagliflozin + metformin + at least one other OAD [D+M+OAD, n=2907 (80.4%), 408 followed-up], while 709 patients (19.6%, 138 followed-up) received dapagliflozin + metformin (D+M). For D+M group, significant mean change was noted for all parameters at follow-up except SBP and DBP (non-significant reductions for HbA1c ≥ 8% subgroup). For D+M+OAD group, significant change was noted for all parameters at follow-up except BMI (non-significant reduction). (Table 1)

Conclusion: Dapagliflozin showed significant improvement in glycemic parameter, BMI and BP when added to metformin, with or without other OADs in real-world.


B.Sethi: None. R.K.Sahay: Advisory Panel; Torrent Pharmaceuticals Ltd, Speaker's Bureau; Novo Nordisk A/S, USV Private Limited, Intas Pharmaceuticals Ltd., Eris Lifesciences Ltd. M.H.Tiwaskar: None. R.Dhediya: None. K.Gaurav: None. R.T.Rathod: None. B.P.Kotak: Employee; Dr. Reddy's Laboratories Ltd. G.D.Dhanaki: None. S.Shah: None.


Dr. Reddy’s Laboratories, Ltd.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at